- Fast Evaluation of Viral Emerging Risks (FEVER): A computational tool for
- 2 biosurveillance, diagnostics, and mutation typing of emerging viral pathogens
- 4 Zachary R. Stromberg, a James Theiler, Brian T. Foley, Adán Myers y Gutiérrez, Attelia
- 5 Hollander, d Samantha J. Courtney, a Jason Gans, d Alina Deshpande, d Ebany J. Martinez-Finley, e
- 6 Jason Mitchell, e Harshini Mukundan, a Karina Yusim, Jessica Z. Kubicek-Sutherlanda, a
- 8 ^a Physical Chemistry and Applied Spectroscopy, Los Alamos National Laboratory, Los Alamos,
- 9 New Mexico, United States
- 10 b Space Data Science and Systems, Los Alamos National Laboratory, Los Alamos, New Mexico,
- 11 United States

3

7

- 13 Mexico, United States
- d Biosecurity and Public Health, Los Alamos National Laboratory, Los Alamos, New Mexico,
- 15 United States

- 16 e Presbyterian Healthcare Services, Albuquerque, New Mexico, United States
- 18 **Short Title**: FEVER tool for detecting emerging viral pathogens
- # Corresponding author: jzk@lanl.gov

ABSTRACT

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

Viral pathogen can rapidly evolve, adapt to novel hosts and evade human immunity. The early detection of emerging viral pathogens through biosurveillance coupled with rapid and accurate diagnostics are required to mitigate global pandemics. However, RNA viruses can mutate rapidly, hampering biosurveillance and diagnostic efforts. Here, we present a novel computational approach called FEVER (Fast Evaluation of Viral Emerging Risks) to design assays that simultaneously accomplish: 1) broad-coverage biosurveillance of an entire class of viruses, 2) accurate diagnosis of an outbreak strain, and 3) mutation typing to detect variants of public health importance. We demonstrate the application of FEVER to generate assays to simultaneously 1) detect sarbecoviruses for biosurveillance; 2) diagnose infections specifically caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and 3) perform rapid mutation typing of the D614G SARS-CoV-2 spike variant associated with increased pathogen transmissibility. These FEVER assays had a high in silico recall (predicted positive) up to 99.7% of 525,708 SARS-CoV-2 sequences analyzed and displayed sensitivities and specificities as high as 92.4% and 100% respectively when validated in 100 clinical samples. The D614G SARS-CoV-2 spike mutation PCR test was able to identify the single nucleotide identity at position 23,403 in the viral genome of 96.6% SARS-CoV-2 positive samples without the need for sequencing. This study demonstrates the utility of FEVER to design assays for biosurveillance, diagnostics, and mutation typing to rapidly detect, track, and mitigate future outbreaks and pandemics caused by emerging viruses.

INTRODUCTION

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

In the last decade, several RNA viruses have emerged from animal reservoirs to threaten global public health (1). These viruses include influenza A in 2009 (2), Ebola in 2013 (3), Chikungunya in 2014 (4), Zika in 2015 (5), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) most recently in 2019 (6, 7). Outbreaks and pandemics often occur when a zoonotic viral strain evolves and escapes human immunity (8, 9). The early detection of these pathogens is required to minimize outbreaks and prevent pandemics by guiding early interventions (10). However, RNA viruses mutate rapidly, so biosurveillance tools must be able to detect groups of viral pathogens with diverse genome sequences and emerging variants, often requiring timeconsuming and expensive procedures performed by trained personnel that are not easily accessible in all regions of the world (11, 12). Once spillover occurs and a viral isolate enters human circulation, a rapid and accurate diagnostic test is required to circumvent its spread (13-16). However, development of accurate diagnostics at the onset of an outbreak can be challenging due to limited data availability depending on the location of the outbreak, and the process for validation and implementation of a new test can also be time-consuming (17). Having a broadly applicable computational approach to assay design that can accommodate pathogen emergence and variant evolution would help alleviate some of these challenges. Coronaviruses are positive-sense, single-stranded RNA viruses and a leading cause of the common cold (18). However, several recent coronavirus outbreaks, including SARS-CoV in 2002-2003, and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, were associated with significant morbidity and mortality (8, 19, 20). In December 2019, SARS-CoV-2 emerged in humans and spread rapidly, resulting in the COVID-19 (coronavirus disease 2019) global pandemic (21-23). SARS-CoV-2, along with SARS-CoV and SARS-like viruses, belong to the subgenus *Sarbecovirus* (24). Effective diagnostic and biosurveillance assays are critical to control the spread of SARS-CoV-2 and prevent future *Sarbecovirus* pandemics.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Real-time reverse transcription PCR (RT-PCR) is considered the gold standard for COVID-19 diagnostics (25) with assays developed by the United States Centers for Disease Control and Prevention (U.S. CDC) (26), China CDC (27), Hong Kong University (28), and Charité Institute of Virology (29), along with commercial products (30). Traditionally, RT-PCR probe and primer design involved selecting a target from a specific gene, often a virulence factor (31). In contrast, modern probe and primer design involves multiple sequence alignments and algorithms to determine conserved signatures for detection (32-34). However, if assays are not updated periodically to account for variants, genome mutations can emerge at the primer or probe binding site and limit assay utility (35, 36). The U.S. CDC initially designed a pan-Sarbecovirus assay targeting the nucleocapsid gene (2019-nCoV N3) with broad coverage, however it eliminated this assay from its diagnostic panel to simplify the testing process (37) and because of cross-reactivity (38) and false-negative results on clinical samples (39). Also, mutations at either a primer or probe binding site (not specified because of proprietary components) yielded falsenegative results for the Roche cobas envelope gene pan-Sarbecovirus assay (36). Finally, mutations have made SARS-CoV-2 more transmissible (40, 41) and potentially more resistant to immunity induced by vaccination (42). The current practice of independently introducing biosurveillance efforts, targeted diagnostics and mutation tracking has hampered our ability to adapt and respond to the dynamic challenges presented by the COVID-19 pandemic. The development of a synchronous approach to integrate these data streams can help mitigate the challenges posed by emerging viral pathogens and support rapid decision making to help combat future outbreaks and pandemics.

There is a critical need for tools that can be used in biosurveillance and diagnostic applications to respond rapidly to emerging pathogens and mitigate their global impact (43). To this end, we have developed FEVER (Fast Evaluation of Viral Emerging Risks), a computational approach that can generate both high-coverage or strain-specific diagnostic assays so that the same detection platform can be used for both broad-based biosurveillance and targeted diagnostic applications. Here, we demonstrate the applicability of FEVER for simultaneous biosurveillance of pan-*Sarbecovirus*es and targeted diagnosis of SARS-CoV-2 in a cohort of 100 human patients. We also demonstrate mutation typing of the D614G SARS-CoV-2 spike variant using this approach as an example of a rapid method for tailored surveillance of pathogen evolution and emergence.

MATERIALS AND METHODS

Ethics. This study was designed in alignment with DOE, NIH, and universal HIPAA guidelines. The protocol was reviewed and approved by the Institutional Review Board of the Los Alamos National Laboratory (LANL#000473), per DOE guidelines and policies, and by the Presbyterian Institutional Review Board (PHS IRB#1608836).

FEVER surveillance and diagnostic probe and primer design. For the surveillance and diagnostics FEVER assays, four sets of primers and probes were generated (Table 1). Two sets of primers and probes were developed for universal detection of all sarbecoviruses, with one targeting the 5' untranslated region (UTR) termed FEVER_5'UTR and another targeting the envelope gene termed FEVER_Env. Another two sets of primers and probes were developed for specific detection of SARS-CoV-2, with one targeting the ORF1ab region termed FEVER_ORF1ab and one targeting the spike gene called FEVER_Spike. After the FEVER probes were designed, primers flanking the probes were created by the PrimerDesign-M tool (44, 45) using an alignment of SARS-CoV-2 sequences.

Table 1. FEVER Assays for COVID-19						
Gene	Primer or probe	Sequence 5' to 3'	Final conc.			
target	name		(nM)			
Pan-Sarbe	covirus detection					
5'UTR	FEVER_5'UTR_F	CTGCTTACGGTTYCGTCCGTGTTGC	500			
	FEVER 5'UTR R	ACTGAGTTGGACGTGTTTTTCTC	500			
	FEVER 5'UTR P	FAM-CTCTCCATC/ZEN/TTACCTTTCGGTCACACCCGG-IABkFQ	250			
Envelope	FEVER_Env_F	CCGACGACTACTAGCG	500			
	FEVER_Env_R	GTTTAGACCAGAAGATCAGGAAC	500			
	FEVER_ Env _P	FAM-CGCACACAA/ZEN/TCGAAGCGCAGTAAGGATGGCT-IABkFQ	250			
Specific SARS-CoV-2 detection						
ORF1ab	FEVER_ORF1ab_F	ATGAAGTATTTTGTGAAAATAGG	500			
	FEVER_ORF1ab_R	CAGCTAGACACCTAGTCATG	500			
	FEVER_ORF1ab_P	FAM-TCTGAAGCA/ZEN/GTGGAAAAGCATGTGGCACGT-IABkFQ	250			
Spike	FEVER_Spike_F	TCCCTCAGGGTTTTTCGGCTTTAG	500			
	FEVER_ Spike _R	GTTTCTGAGAGAGGGTCAAGTGCAC	500			
	FEVER_ Spike _P	FAM-TGCAGCACC/ZEN/AGCTGTCCAACCTGAAGAAGAA-IABkFQ	250			
Mutation typing						
Spike	23403_F	CCAGGAACAAATACTTCTAACCAGGTT	900			
	23403_R	GCATGAATAGCAACAGGGACTTCT	900			
	23403_P1(Wuhan)	VIC-TGTTCTTTATCAGG <u>A</u> TGTTAAC-NFQ	200			

23403 P2(Italy) FAM-TCTTTATCAGGGTGTTAAC-NFQ

Bold/underlined nucleotide indicates the position at which the SNP is detected.

Sequence data. As of March 10, 2020 the Global Initiative on Sharing All Influenza Data (GISAID) database (https://www.epicov.org or https://www.gisaid.org/) had acquired 338 complete, or near-complete, high-quality SARS-CoV-2 genome sequences. After aligning the sequences and eliminating all but one of each set of sequences which were 100% identical to each other to reduce redundancy, our data set consisted of 19 unique sequences of SARS-CoV-2. We also collected all coronaviruses from GenBank that were in the "Sarbecovirus clade" of the beta coronaviruses, using BLAST searches rather than GenBank taxonomy because many sarbecoviruses were listed as "unclassified coronavirus" in the taxonomy table. Again, we reduced redundancy be eliminating identical sequences (primarily many dozens of SARS sequences from the 2003-2004 outbreak), and retained a set of 67 genome sequences. It was these 86 Sarbecovirus genomes that were used to design our assays.

FEVER algorithm. The FEVER algorithm does not require sequence alignments prior to probe design. Instead, our probe design goal was to produce a short nucleotide sequence (called a "k-mer", e.g., a short DNA sequence, k base pairs long) that binds to SARS-CoV-2 without binding to background material that may be present in a sample that is being tested. Specific desirable properties of the probe included maintaining a high GC-content and reducing the hairpin propensity (i.e., the tendency of the probe string to fold over on itself) by ensuring that any self-complementary pairs of sub-strings in the probe are sufficiently short. The mathematical formalization of the problem was expressed in terms of a constrained optimization, with minimum GC-content and the maximum length of self-complementary sub-strings taken as constraints while maximizing coverage. A probe is said to "cover" a SARS-CoV-2 sequence if the probe's k-mer appears as a sub-sequence of that sequence. Thus, coverage is defined as the number of sequences

in the database covered by the probe. "Exact" coverage corresponds to an exact match of probe and sub-sequence. Hamming distance between two strings is defined as the number of characters that would have to be changed in one string to agree with the other string. Given a database of SARS-CoV-2 sequences, the single probe design problem is to find a string of length k, subject to the constraints of GC-content and hairpin aversion, that covers as many SARS-CoV-2 sequences as possible. For the multi-probe design problem, we seek n probes instead of just one, and a n-probe design is said to cover a SARS-CoV-2 sequence if any one of the probes covers it. The selection of k=31 was used because of practical considerations for molecular beacon synthesis allowing for a 12 bp stem region (6 bp on each side of the k-mer). Also, k=31 was long enough to bind to target sequences in the SARS-CoV-2 database without accidentally covering potential background sequences.

Our FEVER algorithm works by extracting all k-mers from each of the sequences in the database and then restricting consideration to those that exhibit a minimal GC-content and hairpin aversion. For every one of these k-mers, we counted how many viral sequences were covered, being careful not to count a sequence twice even if the k-mer appears twice in it. Finally, we selected the k-mer with the largest count. To ensure that our probes were not susceptible to viral mutation, a multi-probe design approach was applied. The first probe was designed using a naïve approach by producing the optimal probe with highest coverage of the queried sequence database. The next probe is designed by eliminating the viral sequences covered by the first probe and using this truncated database to find the single probe that best covers the remaining viral sequences. This process is repeated until 100% of the database is covered. For both pan-Sarbecovirus sequences and SARS-CoV-2 sequences it only took 2 probes to obtain 100% coverage of the sequence database at the time of design.

Data availability. All code written in support of this publication is publicly available at https://github.com/jt-lanl/fever-probes.

FEVER mutation typing probe and primer design. A variant carrying the amino acid change D614G spike mutation became globally dominant, and the G614 variant has been demonstrated to have a fitness advantage associated with higher viral loads (40). A custom TaqMan SNP Genotyping Assay was designed (Thermo Fisher, 4332075) to detect this single nucleotide polymorphism (SNP) in SARS-CoV-2 using Thermo Fisher Scientific's Custom Assay Design Tool. Probe and primer sequences are presented in Table 1.

Analysis of primer and probe coverage. The FEVER biosurveillance and diagnostics assays were computationally characterized using two complementary methods. First, the frequency of SARS-CoV-2 variants in the amplified region of the FEVER and U.S. CDC assays were assessed visually using the Variant Visualizer, which is under development and will be available at https://cov.lanl.gov. Second, we used an *in silico* validation tool (46) to assess the inclusivity of the FEVER assays compared with the U.S. CDC N1 and N2 assays (26). Each assay (forward primer, reverse primer and TaqMan probe) was evaluated against each SARS-CoV-2 sequence from GISAID (47) public database that was greater than 29 kb (n = 525,708) to ensure only complete genomes were assessed. The GISAID sequence data used in this analysis was accessed on February 15, 2021. Results are presented in Table 2. For this analysis, a false-negative was assigned if one or more assay oligonucleotides satisfied any of the following conditions: (i) three or more mismatches to a target sequence, (ii) a predicted melting temperature less than 40°C between the oligonucleotide and a target sequence, or (iii) when primer/target mismatches

occurred in either of the last two 3' bases of a primer associated with an expected increase of 2 or more in the cycle threshold (C_T) value (as defined previously (48)). True-positives were assigned for any assay/target sequence pairing that did *not* result in a false negative. Results are also reported as the number of genome sequences that contained perfect matches, single mismatches, two mismatches, or three or more mismatches for a given assay.

Table 2. <i>In silico</i> inclusivity test against SARS-CoV-2 sequences.						
Assay	Recall (%) ^a	No. sequences with perfect match	No. sequences with 1 mismatch	No. sequences with 2 mismatches	No. sequences that failed ^b	
FEVER 5'UTR	96.39	413,603	91,763	1,361	18,981	
FEVER Env	98.63	511,976	6,164	343	7,225	
FEVER ORF1ab	99.72	490,388	33,723	143	1,454	
FEVER Spike	90.51	360,033	115,321	481	49,873	
U.S. CDC N1	98.95	506,092	11,454	2,633	5,529	
U.S. CDC N2	99.17	507,298	13,901	156	4,353	

Oligonucleotides from each assay were assessed against 525,708 sequences of SARS-CoV-2 obtained from GISAID on February 15, 2021.

Patient sample collection. From November 2020 to December 2020, 100 nasopharyngeal (NP) swabs were collected from individuals suspected of having COVID-19 disease or otherwise randomly tested in the U.S. state of New Mexico. NP swabs were collected using existing U.S. CDC guidelines, labeled with a de-identified bar code, and stored under refrigerated conditions until batch shipping (within 24 hours of sample collection). Specimens were packed and shipped according to U.S. Department of Transportation regulations regarding the shipment of biological substances.

RNA extraction. For spiked samples, RNA extraction was performed using the QIAamp Viral RNA Mini Kit (Qiagen). For the NP swab samples, RNA was extracted using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher) and a KingFisher. For both kits, a 200

^aRecall = true-positive (sum of the perfect match, single mismatch, and double mismatch) / (true-positive + false negative).

^bFailure represents SARS-CoV-2 sequences that were not detected (false-negative).

 μL portion of each sample was used for extraction following the manufacturer's instructions with a 50 μL elution, and 5 μL of the eluted template was used in RT-PCR.

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

RT-PCR protocol. Samples were tested using our FEVER and U.S. CDC 2019-novel coronavirus (2019-nCoV) RT-PCR diagnostic panel (termed U.S. CDC assays) (26). For the U.S. CDC N1 (2019-nCoV N1) and N2 (2019-nCoV N2) assays, each 20 µL reaction consisted of 8.5 μL of water, 1.5 μL of combined primer and probe mix (IDT, 500 nM primer and 125 nM probe, final concentrations), 5 μL of TaqPath 1-step RT-qPCR master mix (Thermo Fisher), and 5 μL of the template. For the FEVER assays (FEVER 5'UTR, FEVER Env, FEVER ORF1ab, and FEVER Spike), each 20 μL reaction consisted of 8 μL of water, 2 μL of combined primer and probe mix (IDT, 500 nM primer and 250 nM probe, final concentrations), 5 μL of TaqPath 1-step RT-qPCR master mix, and 5 µL of the template. The thermocycling conditions were the same for all assays. Thermocycling conditions using an ABI StepOnePlus or 7500 Fast Dx were 25°C for 2 min, 50°C for 15 min, 95°C for 2 min, followed by 45 cycles of 95°C for 3 s and 55°C for 30 s. For RT-PCR assays, samples were considered positive when the C_T value ≤ 40 . Patient clinical samples were considered positive for SARS-CoV-2 when the two U.S. CDC assays N1 and N2 both had a C_T value ≤40, and negative when both targets had a C_T value >40 according to CDC guidelines (37). If only one N1 or N2 result was positive, the result was considered inconclusive and the sample was re-run. If the re-test results were also inconclusive, the final result was reported as inconclusive.

Analytical specificity of RT-PCR. The analytical specificities of the FEVER and U.S. CDC assays were evaluated using genomic RNA from various viruses obtained from BEI

resources. We tested 5 μL of undiluted genomic RNA preparation from SARS-CoV Urbani (NR-52346), avian coronavirus Massachusetts (NR-49096), alphacoronavirus Purdue P115 (NR-48571), porcine respiratory coronavirus ISU-1 (NR-48572), two influenza A viruses (NR-20080 and NR-20081), and two influenza B viruses (NR-45848 and NR-45849). RNA from heat-inactivated SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources, NR-52347) was a positive assay control, and water was a negative assay control.

Analytical sensitivity. The analytical sensitivity of each assay was determined by spiking inactivated SARS-CoV-2 USA-WA1/2020 strain (BEI resources, NR-52286) at 10⁴ copies/μL, and 10-fold serial dilutions were performed in an NP swab matrix. NP swabs from a single human donor (Lee Biosolutions, #991-31-NC-COVID-N) were suspended in 0.45% saline and confirmed SARS-CoV-2 negative by the supplier. Each concentration was tested using three biological replicates.

Assessment of NP swab samples. The 100 NP swab samples were transported to the laboratory for RNA extraction and testing. After RNA extraction, samples were stored at -80°C. Samples were tested by our FEVER and U.S. CDC assays for SARS-CoV-2. For the U.S. CDC assays, the 2019-Ncov plasmid (IDT) containing the nucleocapsid gene was used as a positive control, and water was used as a negative control. For the FEVER assays, RNA from heat-inactivated SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, NR-52347) was used as a positive control, and water was used as a negative control. The RNase P assay described by the U.S. CDC assays (26) was used as an extraction control for each sample.

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Mutation typing of SARS-CoV-2 by PCR. Extracted RNA (10 µL) from SARS-CoV-2 positive patient samples was reverse transcribed in a 20 µL reaction using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher, 4368814) according to the manufacturer's instructions. Each 20 μL SNP genotyping PCR reaction consisted of 5 μL of cDNA as the template, 4.5 μL of water, 0.5 µL of 40× SNP genotyping mix (900 nM primer and 200 nM probe final concentrations), and 10 µL of 2× TaqMan Genotyping Master Mix (Thermo Fisher, 4371353). Amplification was performed using an ABI StepOnePlus RT-PCR machine under the following conditions: 10 min at 95°C and 45 cycles of 15 s at 95°C and 60 s at 60°C in a 96-well plate. The PCR C_T values corresponding with the wild type (VIC) and mutant (FAM) forms were compared, and the lower value (≤45) of the two was determined to be the SNP sequence. Samples were considered undetermined when both reactions had a C_T value >45. Control RNA from Heat-Inactivated SARS-CoV-2, isolate USA-WA1/2020 (BEI Resources, NR-52347) was used as a positive control, diluted to 10⁴ copies/µL, and run with each batch of cDNA synthesis and PCR. Isolate USA-WA1/2020 contains the wild-type spike sequence, and all results with this control showed that the wild-type C_T was lower than the mutant C_T value (data not shown). A total of 17 NP swab samples had sufficient sample volume to be used in sequencing to confirm the D614G mutation. The spike gene was amplified using the 23403F seq and -3' 23403R seq primers (5'-TGAACTTCTACATGCACCAGC 5'and AAACAGCCTGCACGTGTTTG -3', respectively). Each 25 μL reaction consisted of 5 μL of cDNA as the template, 11.75 μL of water, 5 μL of 5X Q5 reaction buffer (New England BioLabs), 0.5 μL of 10 mM dNTPs, 1.25 μL of each primer (0.5 μM final concentration), and 0.25 μL of Q5 hot start high-fidelity DNA polymerase (New England BioLabs). PCR was performed on a thermocycler as follows: 30 s at 95°C and 35 cycles of 10 s at 98°C, 30 s at 65°C, and 30 s at 72°C.

Amplified products were purified using the PureLink PCR Purification Kit (Thermo Fisher, K310002) and were sent for sequencing to Eurofins Genomics.

Statistical analysis. Data were analyzed with GraphPad Prism version 8. Confidence intervals were calculated using the modified Wald method. The Pearson correlation coefficient was used to assess the concordance between PCR C_T values. P values < 0.05 were deemed significant.

RESULTS

FEVER Computational Tool. FEVER combines probes and primers generated to 1) broadly identify an entire class of virus; 2) specifically detect a strain of interest; and 3) detect SNPs of importance to public health. The computational approach starts with a curated multiple sequence alignment. The FEVER algorithm does not however require sequences to be aligned in order to generate assays. The alignment was performed to avoid overrepresentation of any single isolate and ensure broad coverage of the pathogen of interest. In March of 2020, we developed two alignments using the sequences available in GISAID: one with SARS-CoV-2 sequences and one with Sarbecovirus sequences. Of note our FEVER assays were developed within one month of the U.S. CDC assays (41) and also used viral sequence information obtained from GenBank. Next, our FEVER algorithm was applied to design probes using the Sarbecovirus alignment for biosurveillance and the SARS-CoV-2 alignment for diagnostics while also screening the results using parameters set for GC-content, hairpin propensity, and match recall to achieve high coverage as well as reagent manufacturing and performance compatibility. The FEVER algorithm identifies sets of probes that cover 100% of each multiple sequence alignment. Two pan-Sarbecoviruses

(FEVER_5'UTR and FEVER_Env) and two SARS-CoV-2 (FEVER_ORF1ab and FEVER_Spike) specific probes were needed to detect all input sequences. After the FEVER probes were designed, primers flanking the probe sites were designed using the PrimerDesign-M tool (44, 45) for use in RT-PCR assays (Table 1). Few variants were visually detected in the region of amplification of these primers and probes (Fig. S1). Further, we designed TaqMan SNP Genotyping PCR probes and primers to detect the previously identified A23403G (D614G amino acid change) mutation in the spike gene (40) (Table 1). Mutations in the SARS-CoV-2 genome conferring a fitness advantage have been reported (40). However, rapid methods to characterize SARS-CoV-2 mutations are lacking. Together, the primers and probes for all three components (biosurveillance, diagnostics, and mutation typing) are referred to collectively as the FEVER assays.

In silico inclusivity test. We evaluated our FEVER assays using a public web-based validation tool against 525,708 sequences of SARS-CoV-2 (46). The *in silico* evaluation only included complete SARS-CoV-2 genome sequences that were at least 29 kb long. In general, a low number of predicted failures (false-negatives) was observed in comparison with the number of successes or true-positives (total of perfect matches, single mismatch, and double mismatches) (Table 2). Recall (true positives divided by the sum of true positives and false negatives) was used to assess relative assay performance. Of the FEVER and U.S. CDC assays, the SARS-CoV-2 specific FEVER probe targeting ORF1ab had the best-predicted performance with a recall of 99.7%. The pan-Sarbecovirus probe targeting the 5' UTR and envelope gene were also predicted to be highly inclusive for SARS-CoV-2 with recalls of 96.4% and 98.6%, respectively. In contrast, the SARS-CoV-2 specific probe targeting the spike gene had a 90.5% recall, suggesting that the spike gene is a suboptimal target due to its high genetic variability (40, 49). For instance, the U.S.

CDC N1 assay had a recall of 99.0% and the U.S. CDC N2 assay had a 99.2% recall. Compared with the U.S. CDC assays, the FEVER_ORF1ab assay had a ~1% higher recall, FEVER_Env had a similar recall, and the FEVER_5'UTR and FEVER_Spike assays had lower recall values.

Analytical specificity. Cross-reactivity of primers and probes with other microorganisms can reduce the efficacy of RT-PCR (50). For analysis of specificity, SARS-CoV-2 was the only target virus for the SARS-CoV-2 specific assays, and all sarbecoviruses were considered the targets for the pan-*Sarbecovirus* probes. We initially evaluated cross-reactivity *in silico* and then experimentally with non-target viruses. The specificity of each primer and probe set was tested *in silico* using BLAST, which yielded matches to SARS-CoV-2 only for the assay oligonucleotides specific to SARS-CoV-2 (FEVER_ORF1ab and FEVER_Spike) and matches to sarbecoviruses for the pan-*Sarbecovirus* assay oligonucleotides (FEVER_5'UTR and FEVER_Env). No hits to human DNA or other respiratory viruses were found.

For experimental evaluation of specificity, the FEVER assays were tested against three animal coronavirus strains (alphacoronavirus 1 strain Purdue P115, avian coronavirus strain Massachusetts, and porcine respiratory coronavirus strain ISU-1), four influenza virus strains (A/Brisbane/59/2007, A/Brisbane/10/2007, B/Nevada/03/2011, and B/Texas/06/2011), and a single strain of SARS-CoV (Urbani, isolated in 2003). The SARS-CoV-2 strain USA-WA1/2020 was used as a positive control. The three animal coronavirus and four influenza virus strains all tested negative (Table 3). Excluding SARS-CoV-2, the SARS-CoV Urbani strain was the only commercially available genomic RNA from a *Sarbecovirus* available at the time of testing. The SARS-CoV Urbani strain was correctly tested negative by the U.S. CDC assays (N1 and N2), FEVER ORF1ab, and FEVER Spike targets. The SARS-CoV strain Urbani tested positive by the

pan-Sarbecovirus (FEVER_5'UTR and FEVER_Env) FEVER assays, which was expected because these were designed to detect all sarbecoviruses. The SARS-CoV-2 strain USA-WA1/2020 used as a positive control was correctly identified by both FEVER and U.S. CDC assays.

Table 3. Analytical specificity of the FEVER and U.S. CDC assays.								
Virus	Strain	GenBank	FEVER U.S. CDO			CDC		
		Acc. # or Taxon ID ^a	FEVER_ 5'UTR	FEVER_ Env	FEVER_ ORF1ab	FEVER_ Spike	N1	N2
Alphacoronavirus 1	Purdue P115	DQ811788	-	_	_	_	_	_
Avian coronavirus	Massachusetts	GQ504724	_	_	_	_	_	_
Influenza A H1N1	A/Brisbane/59/2007	504904	_	_	_	_	_	_
Influenza A H3N2	A/Brisbane/10/2007	476294	_	_	_	_	_	_
Influenza B Victoria lineage	B/Nevada/03/2011	1308200	_	_	_	_	_	_
Influenza B Yamagata lineage	B/Texas/06/2011	1308263	_	_	_	_	_	_
Porcine respiratory coronavirus	ISU-1	DQ811787	_	_	_	_	_	_
SARS-CoV	Urbani	AY278741	+	+	_	_	_	_
SARS-CoV-2	USA-WA1/2020	MN985325	+	+	+	+	+	+

Abbreviations: +, detected; -, not detected.

Analytical sensitivity in a NP swab matrix. The analytical sensitivity and reproducibility of each assay was tested using standard curves generated by three biological replicates of 10-fold serial dilutions of SARS-CoV-2 spiked into human NP swab samples. The standard curves for RT-PCR in NP swab samples had correlation coefficients (efficiency values) of 0.98 (100.9%) for FEVER_5'UTR, 0.99 (93.7%) for FEVER_Env, 0.99 (96.5%) for FEVER_ORF1ab, 0.99 (98.0%) for FEVER_Spike, 0.99 (103.2%) for N1, and 0.99 (99.1%) for N2, respectively (Fig. 1). We demonstrated that both FEVER and U.S. CDC assays reliably detected SARS-CoV-2 at 1 copy/μL spiked into an NP swab sample matrix.

Comparison of FEVER and U.S. CDC RT-PCR results for clinical NP swab samples. Nasopharyngeal (NP) swab sampling is the recommended sampling method by the World Health Organization (51) for nucleic acid amplification testing of SARS-CoV-2. Viral titers measured in NP swabs vary depending on several factors, including disease progression (52-54). However, NP

^aNCBI Taxon IDs were listed for influenza strains, which did not have a GenBank accession number.

swabs currently remain the reference sample type and support sensitive detection of SARS-CoV-2 (55). Nasopharyngeal swabs from 100 COVID-19 patients were collected in New Mexico, U.S. All assays were run under the same thermocycling conditions as per the U.S. CDC protocol (26). All samples tested positive for the human RNase P gene used as a control to ensure success of the RNA extraction ad associated sample collection methods (Table S1). Of the 100 NP swab samples, 66% (66/100) were considered positive according to the U.S. CDC assays and testing criteria (37), 22 were negative and 12 samples yielded inconclusive results (Table 4). Samples that initially produced an inconclusive result were re-tested and the 12 that remained inconclusive following the second test were removed from the analysis of agreement, sensitivity, and specificity. We compared the four FEVER assays to the results obtained with the U.S. CDC assays and found that all four FEVER assays displayed 100% specificity (no false positives were detected) and varying sensitivities ranging from 74.2% to 92.4% (Table 4, Table S1). However, the U.S. CDC assays were performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, while the FEVER assay was performed in a separate facility on a different thermocycler for research purposes only.

Table 4. FEVER assays compared to the U.S. CDC assays for detection of SARS-CoV-2 in 100 human patient nasopharyngeal swab samples.

		1 1 0	■	
Resulta	FEVER_5'UTR	FEVER_Env	FEVER_ORF1ab	FEVER_Spike
Positive	61	56	56	49
Negative	39	44	44	51
Agreement ^b	94.3% (87.1-97.9%)	87.5% (78.8-93.0%)	88.6% (80.2-93.9%)	80.7% (71.1-87.7%)
Sensitivity ^c	92.4% (83.1-97.1%)	83.3% (72.4-90.6%)	84.8% (74.1-91.8%)	74.2% (62.5-83.3%)
Specificity ^d	100% (84.6-100%)	100% (84.6-100%)	100% (84.6-100%)	100% (84.6-100%)

^a True values are as measured by the U.S. CDC assay criteria (37): 66 positive, 22 negative and 12 inconclusive. Samples initially recorded as inconclusive were re-tested and the 12 that remained inconclusive were removed from the analysis of agreement, sensitivity, and specificity.

352

353

354

355

356

357

358

359

360

361

362

363

364

365

^bAgreement = no. of samples with identical results for an individual FEVER assay and U.S. CDC assay / 88

^cSensitivity = true positive / (true positive + false negative) with 95% confidence intervals

^dSpecificity = true negative / (true negative + false positive) with 95% confidence intervals

^{95%} confidence intervals were calculated using the modified Wald method.

N/A, not applicable.

To directly compare the performance of the FEVER and U.S. CDC assays, 10 samples that contained sufficient remaining RNA were analyzed using both groups of assays on the same ABI StepOnePlus thermocycler in the same laboratory to avoid inter-instrument and inter-laboratory variability. The C_T values of the FEVER assays were plotted against those from the U.S. CDC assay (Fig. 2). In general, a broad range of C_T values from 13 to 39 was observed. Interestingly, one sample that originally tested positive for the U.S. CDC assay (N2) with a C_T value of 34 on the ABI 7500 Fast Dx, tested negative on the ABI StepOnePlus. There was a significant (P < 0.001), correlation between the C_T values of all four FEVER assays compared with each of the U.S. CDC N1 and N2 assays indicating that when run on the same instrument the FEVER and U.S. CDC assays yield highly similar C_T values (Fig. 2). It is unfortunate that this finding occurred after most of the patient samples were exhausted and so not all could be re-tested using the same instrument. These results highlight the importance of using the same instrument when comparing C_T values for assay validation.

D614G mutation typing. High-throughput tracking of SARS-CoV-2 mutations in patient samples may be essential for monitoring the spread of vaccine escape mutants (42). Sequencing can identify novel variants but is too expensive and time-consuming for high-throughput screening of patient samples to track the spread and movement of these variants on a global scale (40). To facilitate a rapid and high-throughput method for monitoring the spread of SNPs of interest, we have incorporated a SNP Genotyping PCR assay. For this mutation typing test, we are detecting the A23403G (D614G amino acid change) mutation in the spike gene, which is associated with greater infectivity (40) (Table 1). Control RNA from isolate USA-WA1/2020 (BEI Resources, NR-52347) was used as a positive control, and results showed that USA-WA1/2020 tested positive

for D614 (data not shown). Of the 59 SARS-CoV-2 positive patient samples (according to the FEVER assays), we determined the SNP at position 23,403 for 57 (96.6%) samples. The G23403 variant was found in 57 samples and 2 samples were undetermined with a C_T cutoff of 45 (Table S2). A fragment of the spike gene was amplified, and the A23403G SNP was confirmed in a subset of samples (n=17) by sequencing (Table S3). These results indicate that most (57/59) patient isolates contained the mutated G614 form of SARS-CoV-2 that became prevalent globally in April 2020 (40).

DISCUSSION

Early detection of emerging pathogens is required to mitigate outbreaks and prevent pandemics (10). Assays used for diagnosing infections are often used for biosurveillance; however, due to their high specificity, they are not usually suited for broad-spectrum surveillance applications or capable of identifying pathogen mutations (43, 56). Therefore, the user must often decide between either obtaining diagnostics or biosurveillance information but not both. FEVER (Fast Evaluation of Viral Emerging Risks) is a computational approach designed to simultaneously facilitate broad-spectrum biosurveillance, pathogen-specific diagnostics, and SNP variant tracking for pandemic response to any viral pathogen of interest. In this manuscript, we demonstrate the application of FEVER to the ongoing COVID-19 pandemic as an initial proof-of-concept. As a proof of concept, we present FEVER assays to detect all sarbecoviruses for future biosurveillance, SARS-CoV-2 for strain-specific diagnostics, and the D614G spike variant SNP mutation associated with increased transmissibility.

Here, we used an RT-PCR format to evaluate the performance of the FEVER assays as compared to the U.S. CDC assays. The success of RT-PCR as a diagnostic approach relies heavily

on the design quality of the primers and probes (57-59) as well as factors such as probe format, the ability to incorporate degenerate nucleotides, the number of target genomes that can be included in the design process to account for genetic diversity, and the ability to avoid cross-reactivity with near-neighbor genomes (60). In the case of SARS-CoV-2 diagnostics, it is also important that assays are able to differentiate infections caused by other common coronaviruses, in which case a false positive could result in unnecessary and costly mitigation procedures (61). For this reason, the U.S. CDC designed its N3 pan-*Sarbecovirus* assay; however, it was unfortunately removed from their assay in March of 2020 in order to expedite reagent manufacturing, consequently removing the biosurveillance component of the U.S. CDC COVID-19 assay (35, 37). This situation highlights the urgent need for a computational approach that can develop both biosurveillance and diagnostics assays that are screened for potential design issues that may potentially affect their performance and manufacturing.

Current probe design methods are also limited by over-representing single isolates in a sequence database as indicated by high coverage *in silico* but assay failure when novel variants emerge (31). In the case of SARS-CoV-2, the high number of false-negative results reported highlights the need for screening and updating assay designs as sequences become available (62-64), which has been a primary goal of https://cov.lanl.gov. Mutations in the probe or primer binding sites are particularly problematics since these can lead to false-negative results and infected individuals may continue to spread the disease (65). Pandemic preparedness requires a balanced approach combining targeted diagnostics assays designed to detect a specific outbreak strain with high-coverage biosurveillance assays that can account for pathogen mutation, and ideally this approach can be utilized to detect a variety of viral pathogens including those that are highly mutagenic. FEVER was designed to fill this void. In the case of SARS CoV-2, our assays

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

were developed within a month of the U.S. CDC assays also using publicly available sequence data, but with a different computational approach in mind. The U.S. CDC designed highly specific diagnostics assays by pre-selecting a single genomic target, the viral nucleocapsid gene, aligned a reference SARS-CoV-2 sequence (GenBank accession no. MN908947), and selected probe/primer sets with low similarity to other coronavirus sequences in GenBank (37). This method has yielded two SARS-CoV-2 specific assays that have contributed to combatting the current pandemic, however it is unclear how useful these assays will be in detecting the next coronavirus outbreak. FEVER takes a more comprehensive approach to design robust multi-purpose assays to detect circulating viral strains and track their mutations but also to detect entire classes of viral pathogens in order to monitor emerging threats. The FEVER algorithm scans the entire viral genome to identify conserved regions and identifies the lowest possible number of probes necessary to cover all sequences scanned. The diagnostics probe FEVER ORF1ab displayed the highest coverage of SARS-CoV-2 sequences in this study with a predicted recall of 99.7%. It was predicted to detect all but 1,454 SARS-CoV-2 sequences out of 525,708 deposited in GISAID as of February 15, 2021. In comparison, the U.S. CDC N2 probe displayed 99.17% coverage and was predicted to fail in 4,353 sequences, which is nearly a 3-fold increase in false-negative results. In addition to optimized sequence analysis, FEVER incorporates physical constraints set by the user to include GC-content, hairpin propensity, sequence length, and even mismatch tolerance. This ensures that probes selected for testing are thermodynamically compatible for increased assay performance as well as future multiplexing. It is critical that assay sensitivity is optimized as a 10-fold increase in the limit of detection for SARS-CoV-2 has shown to result in an increase in the false-negative rate by 13% (66). Here, the limit of detection for both the FEVER

and U.S. CDC assays in NP swab samples was 1 copy/µL which matches previously published

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

findings (26). Additionally, FEVER assay design features can be used to ensure that probes and primers are suitable for large-scale manufacturing and can be tailored to a variety of biosensing platforms, including but not limited to RT-PCR. There is a clear need for the development of rapid and accurate point-of-care diagnostic tools to detect viral infections (67), and a variety of nucleic acid-based viral biosensors are in development for this purpose (43). FEVER also includes a method for rapid mutation typing to track viral variants of public health importance. SARS-CoV-2 has proofreading mechanisms (68) and therefore relatively lower genetic diversity than other respiratory viruses such as influenza (69). For SARS-CoV-2, the predicted evolutionary rate is approximately 8×10⁻⁴ nucleotide substitution per site per year (69). The spike gene is under immune selective pressure as neutralizing antibodies against the protein product can inhibit viral entry into host cells (40, 70). SARS-CoV-2 acquired the D614G mutation in the spike protein early in the pandemic, and this mutation confers greater infectivity (71-73). Previously, the detection of this mutation has been based solely on viral sequencing, which is timeconsuming and cost-prohibitive in many resource limited regions of the world (40, 61, 74, 75). FEVER incorporates a rapid PCR-based method for identifying the D614G mutation directly in patient samples. Similarly, mutation typing probes and primers can be designed in the future to track other variants of interest including the U.K. (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) variants (41, 76, 77) to provide insight and real-time biosurveillance data on the circulation of potential vaccine escape variants. In summary, the FEVER computational approach provides a novel tool to combat emerging viral pathogens. FEVER can be used for simultaneous biosurveillance of viruses, diagnostics of outbreak or pandemic isolates, and mutation typing to rapidly track the spread of variants impacting public health. In addition to PCR, FEVER can generate probes that are compatible with

a wide variety of nucleic acid sensing techniques which may be more suitable to point-of-care testing than RT-PCR (43). Here we show that the FEVER assays are comparable to those designed by the U.S. CDC for the detection of SARS-CoV-2 while simultaneously developing pan-Sarbecovirus assays for future biosurveillance applications. Additionally, FEVER mutation typing assays provide a rapid means for monitoring the spread of potential vaccine escape variants that may significantly impact a population. Future work will focus on applying FEVER towards the development of assays for the detection of other upper respiratory pathogens including influenza as well as testing FEVER probes in ultra-sensitive amplification-free nucleic acid biosensing platforms. FEVER provides a holistic computational approach to combine biosurveillance and diagnostics in order to better combat emerging viral pathogens.

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

SUPPORTING INFORMATION Figure S1. Visualization of SARS-CoV-2 variants in the amplified regions of FEVER and U. S. CDC RT-PCR assays. Near-complete SARS-CoV-2 sequences (n = 299,404) were assessed from GISAID.org. The amplified regions of the FEVER assays (a) FEVER 5'UTR, (b) FEVER Env, (c) FEVER ORF1ab, and (d) FEVER Spike and the U.S. CDC assays (e) N1 and (f) N2 were analyzed for SARS-CoV-2 variants. In each plot, no variants (N/A) were indicated by white and genomic positions containing variants were indicated by colored dots (green, blue, vellow or red). Plots were made using the Variant Visualizer that is under development and will be available at: https://cov.lanl.gov. Table S1. Raw C_T values of FEVER and U.S. CDC assays run on 100 human patient nasopharyngeal swab samples. Table S2. Characterization of the D614G mutation among 59 SARS-CoV-2 positive patient nasopharyngeal swab samples. Table S3. Sequence confirmation of the D614G mutation among 17 selected patient nasopharyngeal swab samples. **ACKNOWLEDGMENTS** This research was funded by Los Alamos National Laboratory Exploratory Research and Development grant number 20190392ER (to J.K.S and K.Y.) and Los Alamos National Laboratory Technology Evaluation and Demonstration Funds. The authors would like to thank the

- Presbyterian Clinical Research team (Brigitte Holder, Susan Salazar, and Maria Vahtel) for their
- 517 contributions to this study. We are also grateful to the patients who volunteered to take part in this
- 518 study.

520

REFERENCES

- 1. Reperant LA, Osterhaus A. 2017. AIDS, Avian flu, SARS, MERS, Ebola, Zika... what next?
- 522 Vaccine 35:4470-4474.
- 523 2. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004.
- Influenza-associated hospitalizations in the United States. JAMA 292:1333-40.
- 3. Feldmann H. 2014. Ebola--a growing threat? N Engl J Med 371:1375-8.
- 4. Delisle E, Rousseau C, Broche B, Leparc-Goffart I, L'Ambert G, Cochet A, Prat C, Foulongne
- V, Ferre JB, Catelinois O, Flusin O, Tchernonog E, Moussion IE, Wiegandt A, Septfons A,
- Mendy A, Moyano MB, Laporte L, Maurel J, Jourdain F, Reynes J, Paty MC, Golliot F. 2015.
- 529 Chikungunya outbreak in Montpellier, France, September to October 2014. Euro Surveill 20.
- 530 5. Ai J-W, Zhang Y, Zhang W. 2016. Zika virus outbreak: 'a perfect storm'. Emerging microbes
- 531 & infections 5:e21-e21.
- 6. LeDuc JW, Barry MA. 2004. SARS, the First Pandemic of the 21st Century. Emerging
- Infectious Diseases 10:e26-e26.
- 7. Carrasco-Hernandez R, Jácome R, López Vidal Y, Ponce de León S. 2017. Are RNA Viruses
- 535 Candidate Agents for the Next Global Pandemic? A Review. ILAR Journal 58:343-358.
- 8. Morens DM, Fauci AS. 2020. Emerging Pandemic Diseases: How We Got to COVID-19. Cell
- 537 182:1077-1092.

- 9. Stromberg ZR, Fischer W, Bradfute SB, Kubicek-Sutherland JZ, Hraber P. 2020. Vaccine
- Advances against Venezuelan, Eastern, and Western Equine Encephalitis Viruses. Vaccines 8.
- 10. Madhav N, Oppenheim B, Gallivan M, Mulembakani P, Rubin E, Wolfe N. 2017. Pandemics:
- Risks, Impacts, and Mitigation. *In Jamison DT*, Gelband H, Horton S, Jha P, Laxminarayan R,
- Mock CN, Nugent R (ed), Disease Control Priorities: Improving Health and Reducing Poverty
- doi:10.1596/978-1-4648-0527-1_ch17, Washington (DC).
- 544 11. Carroll D, Morzaria S, Briand S, Johnson CK, Morens D, Sumption K, Tomori O,
- Wacharphaueasadee S. 2021. Preventing the next pandemic: the power of a global viral
- surveillance network. BMJ 372:n485.
- 547 12. Ibrahim NK. 2020. Epidemiologic surveillance for controlling Covid-19 pandemic: types,
- challenges and implications. Journal of Infection and Public Health 13:1630-1638.
- 13. Kobres P-Y, Chretien J-P, Johansson MA, Morgan JJ, Whung P-Y, Mukundan H, Del Valle
- 550 SY, Forshey BM, Quandelacy TM, Biggerstaff M, Viboud C, Pollett S. 2019. A systematic
- review and evaluation of Zika virus forecasting and prediction research during a public health
- emergency of international concern. PLOS Neglected Tropical Diseases 13:e0007451.
- 553 14. Perkins MD, Dye C, Balasegaram M, Bréchot C, Mombouli JV, Røttingen JA, Tanner M,
- Boehme CC. 2017. Diagnostic preparedness for infectious disease outbreaks. Lancet
- 555 390:2211-2214.
- 15. Manore C, Graham T, Carr A, Feryn A, Jakhar S, Mukundan H, Highlander HC. 2019.
- Modeling and Cost Benefit Analysis to Guide Deployment of POC Diagnostics for Non-
- 558 typhoidal Salmonella Infections with Antimicrobial Resistance. Scientific Reports 9:11245.
- 559 16. Del Valle SY, McMahon BH, Asher J, Hatchett R, Lega JC, Brown HE, Leany ME, Pantazis
- Y, Roberts DJ, Moore S, Peterson AT, Escobar LE, Qiao H, Hengartner NW, Mukundan H.

- 561 2018. Summary results of the 2014-2015 DARPA Chikungunya challenge. BMC Infectious
- 562 Diseases 18:245.
- 563 17. Kelly-Cirino CD, Nkengasong J, Kettler H, Tongio I, Gay-Andrieu F, Escadafal C, Piot P,
- Peeling RW, Gadde R, Boehme C. 2019. Importance of diagnostics in epidemic and pandemic
- preparedness. BMJ global health 4:e001179.
- 18. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. 2018. Host Factors in Coronavirus
- Replication. Curr Top Microbiol Immunol 419:1-42.
- 19. Paules CI, Marston HD, Fauci AS. 2020. Coronavirus Infections-More Than Just the Common
- 569 Cold. JAMA 323:707-708.
- 570 20. Cui J, Li F, Shi Z-L. 2019. Origin and evolution of pathogenic coronaviruses. Nature Reviews
- 571 Microbiology 17:181-192.
- 572 21. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y,
- Yuan M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-
- Z. 2020. A new coronavirus associated with human respiratory disease in China. Nature
- 575 579:265-269.
- 576 22. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
- Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from
- Patients with Pneumonia in China, 2019. N Engl J Med 382:727-733.
- 579 23. Sharma A, Tiwari S, Deb MK, Marty JL. 2020. Severe acute respiratory syndrome
- coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. International
- Journal of Antimicrobial Agents 56:106054-106054.

- 582 24. Fahmi M, Kubota Y, Ito M. 2020. Nonstructural proteins NS7b and NS8 are likely to be
- 583 phylogenetically associated with evolution of 2019-nCoV. Infection, Genetics and Evolution
- 584 81:104272.
- 585 25. Green DA, Zucker J, Westblade LF, Whittier S, Rennert H, Velu P, Craney A, Cushing M, Liu
- D, Sobieszczyk ME, Boehme AK, Sepulveda JL. 2020. Clinical Performance of SARS-CoV-
- 587 2 Molecular Tests. J Clin Microbiol 58.
- 588 26. Centers for Disease Control and Prevention (CDC). 2020. CDC 2019-novel coronavirus
- 589 (2019-nCoV) real-time RT-PCR diagnostic panel. https://www.cdc.gov/coronavirus/2019-
- ncov/lab/rt-pcr-panel-primer-probes.html. Accessed April 6, 2021.
- 591 27. Centers for Disease Control and Prevention (CDC). 2020. National institute for viral disease
- control and prevention. Specific primers and probes for detection of 2019 novel coronavirus.
- 593 <u>http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html</u>. Accessed April 6, 2021.
- 28. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P,
- Wang Q, Peiris M, Poon LLM. 2020. Molecular Diagnosis of a Novel Coronavirus (2019-
- nCoV) Causing an Outbreak of Pneumonia. Clin Chem 66:549-555.
- 597 29. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
- Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
- Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
- Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-
- time RT-PCR. Euro surveillance 25:2000045.
- 30. van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A,
- Molenkamp R, Reusken C, Meijer A. 2020. Comparison of seven commercial RT-PCR
- diagnostic kits for COVID-19. J Clin Virol 128:104412.

- 31. SantaLucia J, Jr., Sozhamannan S, Gans JD, Koehler JW, Soong R, Lin NJ, Xie G, Olson V,
- Roth K, Beck L. 2020. Appendix Q: Recommendations for Developing Molecular Assays for
- Microbial Pathogen Detection Using Modern In Silico Approaches. Journal of AOAC
- 608 INTERNATIONAL 103:882-899.
- 609 32. Medina RA, Rojas M, Tuin A, Huff S, Ferres M, Martinez-Valdebenito C, Godoy P, García-
- Sastre A, Fofanov Y, SantaLucia J, Jr. 2011. Development and characterization of a highly
- specific and sensitive SYBR green reverse transcriptase PCR assay for detection of the 2009
- pandemic H1N1 influenza virus on the basis of sequence signatures. J Clin Microbiol 49:335-
- 613 44.
- 33. Sozhamannan S, Holland MY, Hall AT, Negrón DA, Ivancich M, Koehler JW, Minogue TD,
- 615 Campbell CE, Berger WJ, Christopher GW, Goodwin BG, Smith MA. 2015. Evaluation of
- Signature Erosion in Ebola Virus Due to Genomic Drift and Its Impact on the Performance of
- Diagnostic Assays. Viruses 7:3130-3154.
- 34. Fitch JP, Gardner SN, Kuczmarski TA, Kurtz S, Myers R, Ott LL, Slezak TR, Vitalis EA,
- Zemla AT, McCready PM. 2002. Rapid development of nucleic acid diagnostics. Proceedings
- 620 of the IEEE 90:1708-1721.
- 35. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, Petrone ME, Casanovas-
- Massana A, Catherine Muenker M, Moore AJ, Klein J, Lu P, Lu-Culligan A, Jiang X, Kim DJ,
- Kudo E, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura M,
- Tokuyama M, Venkataraman A, Weizman O-E, Wong P, Yang Y, Cheemarla NR, White EB,
- 625 Lapidus S, Earnest R, Geng B, Vijayakumar P, Odio C, Fournier J, Bermejo S, Farhadian S,
- Dela Cruz CS, Iwasaki A, Ko AI, Landry ML, Foxman EF, Grubaugh ND. 2020. Analytical

- sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. Nature
- 628 Microbiology 5:1299-1305.
- 36. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, Meex C, Melin P, Hayette
- M-P, Bours V, Durkin K. 2020. A Recurrent Mutation at Position 26340 of SARS-CoV-2 Is
- Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a
- 632 Commercial Dual-Target Diagnostic Assay. Journal of Clinical Microbiology 58:e01598-20.
- 633 37. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, Lynch B, Malapati L, Burke
- SA, Harcourt J, Tamin A, Thornburg NJ, Villanueva JM, Lindstrom S. 2020. US CDC Real-
- Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome
- 636 Coronavirus 2. Emerging Infectious Diseases 26:1654-1665.
- 637 38. Babiker A, Myers CW, Hill CE, Guarner J. 2020. SARS-CoV-2 Testing: Trials and
- Tribulations. American Journal of Clinical Pathology 153:706-708.
- 639 39. Nalla AK, Casto AM, Huang MW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H,
- Jerome KR, Greninger AL. 2020. Comparative Performance of SARS-CoV-2 Detection
- Assays Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol 58.
- 40. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi
- EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM,
- de Silva TI, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC,
- Saphire EO, Montefiori DC. 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that
- D614G Increases Infectivity of the COVID-19 Virus. Cell 182:812-827.e19.
- 41. Tang JW, Tambyah PA, Hui DS. 2020. Emergence of a new SARS-CoV-2 variant in the UK.
- 648 J Infect 82:e27-e28.

- 42. Williams TC, Burgers WA. 2021. SARS-CoV-2 evolution and vaccines: cause for concern?
- 650 Lancet Respir Med 9:333-335.
- 43. Courtney SJ, Stromberg ZR, Kubicek-Sutherland JZ. 2021. Nucleic Acid-Based Sensing
- Techniques for Diagnostics and Surveillance of Influenza. Biosensors (Basel) 11:47.
- 44. Yoon H, Leitner T. 2015. PrimerDesign-M: a multiple-alignment based multiple-primer design
- tool for walking across variable genomes. Bioinformatics 31:1472-1474.
- 45. Brodin J, Krishnamoorthy M, Athreya G, Fischer W, Hraber P, Gleasner C, Green L, Korber
- B, Leitner T. 2013. A multiple-alignment based primer design algorithm for genetically highly
- variable DNA targets. BMC Bioinformatics 14:255.
- 46. Li P-E, Myers y Gutiérrez A, Davenport K, Flynn M, Hu B, Lo C-C, Player Jackson E, Shakya
- M, Xu Y, Gans JD, Chain PSG. 2020. A public website for the automated assessment and
- of validation of SARS-CoV-2 diagnostic PCR assays. Bioinformatics
- doi:10.1093/bioinformatics/btaa710.
- 47. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data from vision
- to reality. Euro surveillance 22:30494.
- 48. Li B, Kadura I, Fu DJ, Watson DE. 2004. Genotyping with TaqMAMA. Genomics 83:311-
- 665 320.
- 49. Peñarrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Manissero D, López-Fontanals
- M, Pareja J. 2020. Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the
- risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect
- 669 Dis 97:225-229.

- 50. Qian J, Boswell SA, Chidley C, Lu Z-x, Pettit ME, Gaudio BL, Fajnzylber JM, Ingram RT,
- Ward RH, Li JZ. 2020. An enhanced isothermal amplification assay for viral detection. Nature
- 672 Communications 11:5920.
- 51. World Health Organization. 2020. Laboratory testing for 2019 novel coronavirus (2019-
- 674 nCoV) in suspected human cases, Interim guidance, 2 March 2020.
- https://www.who.int/publications/i/item/10665-331501. Accessed 05/11/2021.
- 52. Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami S, Barati
- S, Crowl G, Faheem A, Farooqi L, Khan S, Prost K, Poutanen S, Taylor M, Yip L, Zhong XZ,
- McGeer AJ, Mubareka S. 2021. Sensitivity of Nasopharyngeal Swabs and Saliva for the
- Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Clin Infect Dis 72:1064-
- 680 1066.
- 53. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P,
- Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone ME, Ott IM, Lu P,
- Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M, Datta R, Handoko R,
- Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S, Kalinich CC, Jiang X, Kim DJ,
- Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park A, Silva J, Song E, Takahashi T, Taura
- M, Weizman OE, Wong P, Yang Y, Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian
- S, Martinello RA, Iwasaki A, Grubaugh ND, et al. 2020. Saliva or Nasopharyngeal Swab
- Specimens for Detection of SARS-CoV-2. N Engl J Med 383:1283-1286.
- 54. Klausner JD, Kojima N, Butler-Wu SM. 2021. Is the Patient Infected with SARS-CoV-2?
- Journal of Clinical Microbiology 59:e00147-21.

- 55. Bastos ML, Perlman-Arrow S, Menzies D, Campbell JR. 2021. The Sensitivity and Costs of
- Testing for SARS-CoV-2 Infection With Saliva Versus Nasopharyngeal Swabs : A Systematic
- Review and Meta-analysis. Ann Intern Med 174:501-510.
- 56. Hammou RA, Benhassou M, Bessi H, Ennaji MM. 2020. Chapter 7 Scientific Advances in
- the Diagnosis of Emerging and Reemerging Viral Human Pathogens, p 93-120. *In* Ennaji MM
- (ed), Emerging and Reemerging Viral Pathogens doi:10.1016/B978-0-12-814966-9.00007-X.
- 697 Academic Press.
- 698 57. Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. 2012. Primer-BLAST: a
- tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics
- 700 13:134.
- 701 58. Hendling M, Pabinger S, Peters K, Wolff N, Conzemius R, Barišic I. 2018. Oli2go: an
- automated multiplex oligonucleotide design tool. Nucleic Acids Res 46:W252-W256.
- 59. Lopez-Rincon A, Tonda A, Mendoza-Maldonado L, Mulders DGJC, Molenkamp R, Perez-
- Romero CA, Claassen E, Garssen J, Kraneveld AD. 2021. Classification and specific primer
- design for accurate detection of SARS-CoV-2 using deep learning. Scientific Reports 11:947.
- 706 60. Li D, Zhang J, Li J. 2020. Primer design for quantitative real-time PCR for the emerging
- 707 Coronavirus SARS-CoV-2. Theranostics 10:7150-7162.
- 708 61. Isabel S, Graña-Miraglia L, Gutierrez JM, Bundalovic-Torma C, Groves HE, Isabel MR,
- Eshaghi A, Patel SN, Gubbay JB, Poutanen T, Guttman DS, Poutanen SM. 2020. Evolutionary
- and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented
- worldwide. Scientific Reports 10:14031.
- 712 62. Albert E, Ferrer B, Torres I, Serrano A, Alcaraz MJ, Buesa J, Solano C, Colomina J, Bueno F,
- Huntley D, Olea B, Valdivia A, Navarro D. 2021. Amplification of human β-glucuronidase

- gene for appraising the accuracy of negative SARS-CoV-2 RT-PCR results in upper
- respiratory tract specimens. J Med Virol 93:48-50.
- 716 63. Gietema HA, Zelis N, Nobel JM, Lambriks LJG, van Alphen LB, Oude Lashof AML,
- Wildberger JE, Nelissen IC, Stassen PM. 2020. CT in relation to RT-PCR in diagnosing
- 718 COVID-19 in The Netherlands: A prospective study. PloS One 15:e0235844-e0235844.
- 719 64. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the
- Northwell C-RC. 2020. Presenting Characteristics, Comorbidities, and Outcomes Among 5700
- Patients Hospitalized With COVID-19 in the New York City Area. JAMA 323:2052-2059.
- 722 65. Woloshin S, Patel N, Kesselheim AS. 2020. False Negative Tests for SARS-CoV-2 Infection
- Challenges and Implications. N Engl J Med 383:e38.
- 66. Arnaout R, Lee RA, Lee GR, Callahan C, Cheng A, Yen CF, Smith KP, Arora R, Kirby JE.
- 725 2021. The Limit of Detection Matters: The Case for Benchmarking Severe Acute Respiratory
- 726 Syndrome Coronavirus 2 Testing. Clin Infect Dis doi:10.1093/cid/ciaa1382.
- 727 67. Ravi N, Cortade DL, Ng E, Wang SX. 2020. Diagnostics for SARS-CoV-2 detection: A
- comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron
- 729 165:112454-112454.
- 730 68. Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL. 2020.
- Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol Cell
- 732 79:710-727.
- 69. MacLean OA, Orton RJ, Singer JB, Robertson DL. 2020. No evidence for distinct types in the
- evolution of SARS-CoV-2. Virus Evolution 6.
- 735 70. Lo Presti A, Rezza G, Stefanelli P. 2020. Selective pressure on SARS-CoV-2 protein coding
- genes and glycosylation site prediction. Heliyon 6:e05001.

- 737 71. Weissman D, Alameh MG, de Silva T, Collini P, Hornsby H, Brown R, LaBranche CC,
- Edwards RJ, Sutherland L, Santra S, Mansouri K, Gobeil S, McDanal C, Pardi N, Hengartner
- N, Lin PJC, Tam Y, Shaw PA, Lewis MG, Boesler C, Şahin U, Acharya P, Haynes BF, Korber
- B, Montefiori DC. 2020. D614G Spike Mutation Increases SARS CoV-2 Susceptibility to
- Neutralization. Cell Host Microbe 29:23-31.e4.
- 742 72. Mansbach RA, Chakraborty S, Nguyen K, Montefiori DC, Korber B, Gnanakaran S. 2021. The
- SARS-CoV-2 Spike variant D614G favors an open conformational state. Science Advances
- 744 7:eabf3671.
- 745 73. Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J,
- Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg
- AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi P-Y. 2020. Spike mutation D614G
- 748 alters SARS-CoV-2 fitness. Nature 592:116-121.
- 749 74. Gong YN, Tsao KC, Hsiao MJ, Huang CG, Huang PN, Huang PW, Lee KM, Liu YC, Yang
- SL, Kuo RL, Chen KF, Liu YC, Huang SY, Huang HI, Liu MT, Yang JR, Chiu CH, Yang CT,
- 751 Chen GW, Shih SR. 2020. SARS-CoV-2 genomic surveillance in Taiwan revealed novel
- ORF8-deletion mutant and clade possibly associated with infections in Middle East. Emerg
- 753 Microbes Infect 9:1457-1466.
- 75. Slezak T, Kuczmarski T, Ott L, Torres C, Medeiros D, Smith J, Truitt B, Mulakken N, Lam
- 755 M, Vitalis E, Zemla A, Zhou CE, Gardner S. 2003. Comparative genomics tools applied to
- bioterrorism defence. Briefings in Bioinformatics 4:133-149.
- 757 76. Tang JW, Toovey OTR, Harvey KN, Hui DDS. 2021. Introduction of the South African SARS-
- CoV-2 variant 501Y.V2 into the UK. The Journal of infection 82:e8-e10.

77. La Rosa G, Mancini P, Bonanno Ferraro G, Veneri C, Iaconelli M, Lucentini L, Bonadonna L, Brusaferro S, Brandtner D, Fasanella A, Pace L, Parisi A, Galante D, Suffredini E. 2021. Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. Water Res 197:117104.

FIGURES

765

766

767

768

769




Figure 1. FEVER assays can detect 1 copy/µL SARS-CoV-2 spiked into a nasopharyngeal swab sample matrix. Inactivated SARS-CoV-2 strain USA-WA1/2020 was spiked into human nasopharyngeal swab samples (confirmed to be SARS-CoV-2 negative) and serial 10-fold diluted from 10⁴ to 1 copies/μL. Cycle threshold (C_T) values were determined for FEVER assays (blue dots) (a) FEVER 5'UTR, (b) FEVER Env, (c) FEVER ORF1ab, and (d) FEVER Spike and the (a) N1 and (b) N2 assay described by the U.S. CDC (black dots).




Figure 2. The FEVER and U.S. CDC assays show concordance in detecting SARS-CoV-2 in patient nasopharyngeal swab samples. The U.S. CDC N1 cycle threshold (C_T) values were compared to (a) FEVER_5'UTR, (b) FEVER_Env, (c) FEVER_ORF1ab, and (d) FEVER_Spike RT-PCR assays C_T values (blue dots). The U.S. CDC N2 C_T values were compared to (e) FEVER_5'UTR, (f) FEVER_Env, (g) FEVER_ORF1ab, and (h) FEVER_Spike RT-PCR assays C_T values (purple dots). One sample was removed for the N2 vs FEVER_ORF1ab and N2 vs FEVER_Spike comparisons because it was not detected by these assays. Each dot represents an individual sample. Dotted lines represent the limit of detection. ND, not detected.